CD19 and diffuse large B-cell lymphoma: CD19 targeted CAR T cells have been approved for the treatment of acute lymphoblastic leukaemia [193], relapsed/refractory diffuse large B-cell lymphoma [194,195,196] and relapsed/refractory follicular lymphoma [197].